Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women

References

• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745–2749.
   PubMed Web of Science ®Google Scholar
• Orio F, Palomba S, Spinelli L Jr., et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab. 2004;89(8):3696–3701.
   PubMed Web of Science ®Google Scholar
• Orio F, Palomba S. Reproductive endocrinology: new guidelines for the diagnosis and treatment of PCOS. Nat Rev Endocrinol. 2014;10(3):130–132.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165–1174.
   PubMed Web of Science ®Google Scholar
• El Hayek S, Bitar L, Hamdar LH, et al. Poly cystic ovarian syndrome: an updated overview. Front Physiol. 2016;7:124.
   PubMed Web of Science ®Google Scholar
• Thomas MP, Mills SJ, Potter BV. The “Other” inositols and their phosphates: synthesis, biology, and medicine (with recent advances in myo-inositol chemistry). Angew Chem Int Ed Engl. 2016;55(5):1614–1650.
   PubMed Web of Science ®Google Scholar
• Unfer V, Facchinetti F, Orrù B, et al. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647–658.
   PubMed Web of Science ®Google Scholar
• Muscogiuri G, Palomba S, Laganà AS, et al. Inositols in the treatment of insulin-mediated diseases. Int J Endocrinol. 2016;2016:3058393.
   PubMed Web of Science ®Google Scholar
• Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006;443(7112):651–657.
   PubMed Web of Science ®Google Scholar
• Costantino D, Minozzi G, Minozzi E, et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009;13(2):105–110.
   PubMed Web of Science ®Google Scholar
• Sun T-h, Heimark DB, Nguygen T, et al. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun. 2002;293(3):1092–1098.
   PubMed Web of Science ®Google Scholar
• Larner J, Craig JW. Urinary myo-inositol-to-chiro-inositol ratios and insulin resistance. Diabetes Care. 1996;19(1):76–78.
   PubMed Web of Science ®Google Scholar
• Iuorno MJ, Jakubowicz DJ, Baillargeon J-P, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002;8(6):417–423.
   PubMedGoogle Scholar
• Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340(17):1314–1320.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Iuorno MJ. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2000;13(Suppl. 5):1295–1298.
   PubMedGoogle Scholar
• Masharani U, Gjerde C, Evans JL, et al. Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol. 2010;4(2):359–364.
   PubMedGoogle Scholar
• Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 2018;182:27–36.
   PubMed Web of Science ®Google Scholar
• Sabuncu T, Vural H, Harma M, et al. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem. 2001;34(5):407–413.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Shefer K, Della Casa D, et al. Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. J Endocrinol Invest. 2018;41(5):583–590.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47.
   PubMed Web of Science ®Google Scholar
• Classification BMI. Global database on body mass index. Geneva: World Health Organization; 2006.
   Google Scholar
• Genazzani AD. Inositol as putative integrative treatment for PCOS. Reprod Biomed Online. 2016;33(6):770–780.
   PubMed Web of Science ®Google Scholar
• Unfer V, Porcaro G. Updates on the myo-inositol plus d-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2014;7(5):623–631.
   PubMed Web of Science ®Google Scholar
• Nordio M, Proietti E. The combined therapy with myo-inositol and d-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012;16(5):575–581.
   PubMed Web of Science ®Google Scholar
• Colazingari S, Treglia M, Najjar R, et al. The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013;288(6):1405–1411.
   PubMed Web of Science ®Google Scholar
• Unfer V, Carlomagno G, Rizzo P, et al. Myo-inositol rather than d-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci. 2011;15(4):452–457.
   PubMed Web of Science ®Google Scholar
• Piomboni P, Focarelli R, Capaldo A, et al. Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: the effect of inositol and metformin. J Assist Reprod Genet. 2014;31(10):1269–1276.
   PubMed Web of Science ®Google Scholar
• Mendoza N, Pérez L, Simoncini T, et al. Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials. Reprod Biomed Online. 2017;35(5):529–535.
   PubMed Web of Science ®Google Scholar
• Bevilacqua A, Dragotto J, Giuliani A, et al. Myo-inositol and d-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. J Cell Physiol. 2019;234(6):9387–9398.
   PubMed Web of Science ®Google Scholar
• Mendoza N, Diaz-Ropero MP, Aragon M, et al. Comparison of the effect of two combinations of myo-inositol and d-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2019;35(8):695–700.
   PubMed Web of Science ®Google Scholar
• Artini PG, Di Berardino OM, Papini F, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013;29(4):375–379.
   PubMed Web of Science ®Google Scholar
• Crespo RP, Bachega TASS, Mendonça BB, et al. An update of genetic basis of PCOS pathogenesis. Arch Endocrinol Metab. 2018;62(3):352–361.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Lanzoni C, Ricchieri F, et al. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24(3):139–144.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Prati A, Simoncini P, et al. Modulatory role of d-chiro-inositol and alpha lipoic acid combination on hormonal and metabolic parameters of overweight/obese PCOS patients. Eur Gynecol Obstet. 2019;1:29–33.
   Google Scholar
• Genazzani AD, Santagni S, Rattighieri E, et al. Modulatory role of d-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol. 2014;30(6):438–443.
   PubMed Web of Science ®Google Scholar
• Katsikis I, Karkanaki A, Misichronis G, et al. Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2011;156(2):181–185.
   PubMed Web of Science ®Google Scholar
• Pasquali R. Metabolic syndrome in polycystic ovary syndrome. Front Horm Res. 2018;49:114–130.
   PubMed Web of Science ®Google Scholar
• Cela V, Obino MER, Alberga Y, et al. Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes. Gynecol Endocrinol. 2018;34(6):518–523.
   PubMed Web of Science ®Google Scholar
• Mendoza N, Galan MI, Molina C, et al. High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2019;1–4.
   PubMed Web of Science ®Google Scholar